Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL128388 | 0.78 | NQO1 (0.46) | TP53CYP3A4TSHRTDP1MAPT | |
| SCHEMBL11513183 | 0.78 | NQO1 (0.36) | TP53CYP3A4TSHRTDP1MAPT | |
| SCHEMBL2890991 | 0.77 | — | — | |
| SCHEMBL160927 | 0.76 | NQO1 (0.34) | TDP1L3MBTL1NQO1HTT | |
| SCHEMBL7774207 | 0.76 | HPGD (0.37) | TSHRMAPTGAAMEN1KMT2A | |
| SCHEMBL3048684 | 0.76 | LTA4H (0.38) | TSHRMAPTKDM4EGAAMEN1 | |
| SCHEMBL15352630 | 0.76 | NQO1 (0.34) | NQO1 | |
| SCHEMBL157423 | 0.76 | TSHR (0.37) | TSHRTDP1MAPTKDM4EGAA | |
| SCHEMBL7690729 | 0.76 | NQO1 (0.34) | TP53POLBNQO1 | |
| SCHEMBL5655861 | 0.76 | ALDH1A1 (0.47) | TSHRMAPTKDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111377907-B | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-111377907-A | Polysubstituted phenylamino pyrimidine derivative and preparation method and application thereof | 杭州百新生物医药科技有限公司 | 2020-07-07 | — | — | CN | disclosed |
| WO-2020135507-A1 | POLYSUBSTITUTED ANILINOPYRIMIDINE DERIVATIVE AND PREPARATION METHOD AND APPLICATION THEREOF | 杭州百新生物医药科技有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-6800630-B2 | CYTOSTATIC ACTIVITY, INHIBITORY ACTIVITY AGAINST A SIGNAL DERIVED FROM RAS ONCOGENE PRODUCTS | SHIONOGI & CO., LTD. (JP) | 2004-10-05 | — | — | US | disclosed |
| EP-1251129-B1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO (JP) | 2004-06-09 | — | — | EP | disclosed |
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | SHIONOGI & CO., LTD. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1251129-A1 | PYRIMIDINE DERIVATIVES HAVING ANTITUMOR EFFECT | SHIONOGI & CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-6420367-B1 | RAS GENE | SHIONOGO & CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1097933-A1 | PYRIMIDINE DERIVATIVES EXHIBITING ANTITUMOR ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2001-05-09 | — | — | EP | disclosed |
| US-4001306-A | INHIBITION OF PLATELET AGGREGATION; NASAL PATENCY, LABOR INDUCEMENT, CONTROLLING BLOOD PRESSURE | THE UPJOHN COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203894-A1 | Pyrimidine derivatives having antitumor effect | TYMS, TYMP, RRM1 | TP53 63/4885CYP3A4 423/4885TSHR 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.